FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
This article was originally published in The Tan Sheet
Executive Summary
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA